AGE Reader

Literature References

SMT medical GmbH&Co.
Im Kreuz 9 • 97076 Wuerzburg • Germany
Tel. +49 (931) 3 29 33-0 Fax • +49 (931) 3 29 33-29
www.smt-medical.com • info@smt-medical.com

AGE Reader Key Publications

- **Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study.**
  van Waateringe R. et al. Eur J Clin Invest. 2016 Mar 22. Epub.
- **Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.**
  Lutgers H. et al, Diabetologia, 2009; 52(5): 789-797
- **Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.**
  Noordzij M.J. et al. Diabet Med. 2012 Dec;29(12):1556-61.
- **Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3.**
  McIntyre N. et al. Clin J Am Soc Nephrol. 2011 Sep 1. Epub
- **Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease.**
  Gerrits E. et al. Diabetes Care. 2008; 31: 517-521
- **Messung der Autofluoreszenz der Haut.**
  Stirban A. and Heinemann L. Diabetes Stoffw Herz. 2013; 22 (full text available)
- **Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease.**
  de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13.
- **Simple non-invasive assessment of advanced glycation endproducts accumulation.**
  Meerwaldt R et al, Diabetologia, 2004; 47:1324-1330

AGE Reader in diabetes

1. **The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients.**
   Li Z. et al. Biosci Rep. 2017 Apr 13. doi: 10.1042/BSR20170213.
2. **Vitreous advanced glycation endproducts and α-dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls.**
   Fokkens B.T. et al. PLoS One. 2017 Mar 6;12(3):e0173379. doi: 10.1371/journal.pone.0173379.
3. **Skin autofluorescence, renal insufficiency and retinopathy in patients with type 2 diabetes.**
   Bentata R. et al. J Diabetes Complications. 2016 Oct 30. [Epub ahead of print]
4. **Association between small fiber neuropathy and higher skin accumulation of advanced glycation end products in patients with type 1 diabetes.**
   Araszkiewicz A, et al. Pol Arch Med Wewn. 2016 Nov 22;126(11):847-853.
5. **Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance.**
   Dimova R, et al. J Diabetes Complications. 2016 Nov 6. [Epub ahead of print]
6. **Skin autofluorescence (a marker for advanced glycation end products) and erectile dysfunction in diabetes.**
   Kouidrat Y. et al. J Diabetes Complications. 2016 Oct 29. pii: S1056-8727(16)30351-8. [Epub ahead of print]
7. **Skin autofluorescence is increased in young people with type 1 diabetes exposed to secondhand smoking.**
   Vollenbrock CE. et al. J Diabetes. 2016 Oct 27. (Epub).
8. **Higher skin autofluorescence in young people with Type 1 diabetes and microvascular complications.**
   Cho YH. et al. Diabet Med. 2016 Oct 22. (Epub)

9. **Advanced glycation end products is a risk for muscle weakness in Japanese patients with type 1 diabetes.** Mori H. et al. J Diabetes Investig. 2016 Oct 11. (Epub) (FULL TEXT available)

10. **Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes.** Osawa S et al. J Atheroscler Thromb. 2016 Sep 2.

11. **Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study.** Vélayoudom-Céphise FL et al. Cardiovasc Diabetol. 2016 Sep 1;15(1):127.

12. **Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study.** van Eupen MG et al. Hypertension. 2016 Oct;68(4):956-63.

13. **Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.** Fokkens BT, Smit AJ. Glycoconj J. 2016 Aug;33(4):527-35.

14. **ADVANCED GLYCATION END PRODUCT (AGE) ACCUMULATION IN THE SKIN IS ASSOCIATED WITH DEPRESSION: THE MAASTRICHT STUDY.** van Dooren FE et al. Depress Anxiety. 2016 Jun 6. (Epub)

15. **Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes.** Rajaobelina K. et al. Diabetes Metab Res Rev. 2016 May 27. Epub

16. **The relationship between advanced glycation endproducts and ocular circulation in type 2 diabetes.** Hashimoto K. et al. J Diabetes Complications 2016 May 4. Epub.

17. **Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes.** Furst J.R. et al. J Clin Endocrinol Metab. 2016 Apr 26. Epub.

18. **Association of Advanced Glycation End Products with coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence.** Hangai M. et al. J Atheroscler Thromb. 2016 Mar 10.

19. **Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes.** Temma J. et al. J Med Invest. 2015;62(3-4):126-9.

20. **Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus.** Banser A. et al. Pediatr Diabetes. 2015 Sep 2.

21. **Relationship between skin auto fluorescence and conventional glycemic markers in patients with diabetes.** Mácsai E. et al. Orv Hetil. 2015 Aug 16;156(33):1341-7.

22. **In diabetic Charcot neuroarthropathy impaired microvascular function is related to long lasting metabolic control and low grade inflammatory process.** Araszkiewicz A. et al. Microvasc Res. 2015 Aug 1;101:143-147.

23. **Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report.** Krul-Poel Y.H. et al. Cardiovasc Diabetol. 2015 Jul 16;14:89.

24. **Is skin autofluorescence a marker of metabolic memory in pregnant women with diabetes?** Maury E. et al. Diabet Med. 2015 May 16.

25. **The Association Between Skin Autofluorescence and Vascular Complications in Chinese Patients With Diabetic Foot Ulcer: An Observational Study Done in Shanghai.** Liu C. et al. Int J Low Extrem Wounds. 2015. (Epub)

26. **Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population.** Rajaobelina K. et al. J Gerontol A Biol Sci Med Sci. 2015 Jan 14 (Epub)

27. **Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study.** Araszkiewicz A. et al. Microvasc Res. 2015 Jan 10 (Epub)

28. **Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes.** Rigalleau V. et al. J Diabetes Complications. 2014 Oct 30. Epub

29. **Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease.**
Bakker S.F. et al. Nutr Metab Cardiovasc Dis. 2014 Nov 1.Epub

30. **Associations of advanced glycation endproducts with cognitive functions in individuals with and without type 2 diabetes.**
Spauwen P.J. et al. J Clin Endocrinol Metab. 2014 Dec 2

31. **Relationship of Skin Autofluorescence to Severity of Retinopathy in Type 2 Diabetes.**
Yasuda M. et al. Curr Eye Res. 2014 May 28:1-8.

32. **Type 2 diabetes mellitus, skin autofluorescence and brain atrophy.**
Moran C. et al. Diabetes. 2014 Jul 22.

33. **AGEs and chronic subclinical inflammation in diabetes: disorders of immune system.**
Hu H. et al. Diabetes Metab Res Rev. 2014 May 20. Epub

34. **Correlation between diabetic makuls severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients.**
Hirano T. et al. J Diabetes Complications. 2014 Mar 10. Epub

35. **Advanced glycation end products are associated with arterial stiffness in type 1 diabetes.**
Llauradó G. et al. J Endocrinol. 2014 Jun;221(3):405-13.

36. **Messung der Autofluoreszenz der Haut.**
Stirban A. and Heinemann L. Diabetes Stoffw Herz. 2013; 22 (full text available)

37. **Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.**
Skrha J Jr. et al. J Diabetes Res. Epub 2013 Mar 10.

38. **Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes.**
Smit AJ. et al. PLoS One. 2013 Jun 4;8(6):e65592.

39. **Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.**
Fukami K. Rejuvenation Res. 2013 Aug 4. [Epub ahead of print]

40. **Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.**
Skrha J Jr. et al. J Diabetes Res. 2013;2013:650694.

41. **Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus.**
Genevieve M. et al. Diabetes Metab. 2013 May 2. [Epub ahead of print]

42. **Advanced Glycation End Products Assessed by Skin Autofluorescence-A New Marker of Diabetic Foot Ulceration.**
Vouillarmet J. et al. Diabetes Technol Ther. 2013 Apr 30. [Epub ahead of print]

43. **Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2.**
Dörhöfer L, BMC Med Genet. 2013 Feb 14;14:25.

44. **Verification of Skin Autofluorescence Values by Mass Spectrometry in Adolescents with Type 1 Diabetes: Brief Report.**
Mácsai E. et al.Diabetes Technol Ther. 2013 Jan 23.

45. **Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption.**
Klenovics KS. et al.PLoS One. 2013;8(1):e53056.

46. **Advanced Glycation End Products, Measured as Skin Autofluorescence, During Normal Pregnancy and Pregnancy Complicated by Diabetes Mellitus.**
de Ranitz-Greven WL. et al. Diabetes Technol Ther. 2012 Oct 31. (Epub)

47. **Skin autofluorescence measurement in diabetological and nephrological clinical practice.**
Mácsai E. et al. Orv Hetil. 2012 Oct 21;153(42):1651-7.

48. **Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.**
Noordzij M.J. et al. Diabet Med. 2012 Aug 31. doi: 10.1111/dme.12005.

49. **Advanced glycation end products measured by skin autofluorescence in a population with central obesity.**
den Engelsen C. et al. Dermatoendocrinol. 2012 Jan 1;4(1):33-8.

50. **Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects.**
Hu H. et al. J Zhejiang Univ Sci B. 2012 May;13(5):372-7.

51. **Advanced Glycation Endproducts and Diabetic Cardiovascular Disease.**
Prasad A. et al. Cardiol Rev. 2012 Feb 6. Epub

52. **Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction.**
Januszewski A.S. et al. Diabet Med. 2011 Dec 28. doi: 10.1111/j.1464-5491.2011.03562.x.

53. **Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes.** Tanaka K. et al. Diabet Med. 2011 Sep 14. Epub

54. **Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus.**
Mulder D. et al. Atherosclerosis. 2011 May, Epub

55. **Advanced Glycation End Products, Measured as Skin Autofluorescence, at Diagnosis in Gestational Diabetes Mellitus Compared with Normal Pregnancy.**
de Ranitz-Greven WL et al. Diabetes Technol Ther. 2011 Aug 29. Epub

56. **Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes.**
Araszkiewicz A. et al. Diabetes Technol Ther. 2011 Aug;13(8):837-42.

57. **Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes.**
Samborski P. et al. Pol Arch Med Wewn. 2011 Mar;121(3):67-72.

58. **Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review.**
Bos D.C. et al. Diabetes Technol Ther. 2011 Jul;13(7):773-9.

59. **Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients.**
Willemsen S. et al. Eur J. Heart Fail 2010. doi:10.1093/eurjhf/hfq168

60. **Skin autofluorescence and glycemic variability.**
Noordzij M. et al. Diabetes Technol Ther. 2010; 12(7): 581-585

61. **Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy.**
Chabroux S. et al: Diabetes Metab, 2010 Apr;36(2):152-7.

62. **Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus**
Lutgers H. et al: Diabetologia, 2009; 52(5): 789-797

63. **Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease.**
Gerrits E. et al. Diabetes Care. 2008; 31: 517-521

64. **Skin autofluorescence is a strong predictor of cardiac mortality in diabetes**
Meerwaldt R, et al. Diabetes Care 2007, 30: 107-112

65. **Skin autofluorescence in type 2 diabetes: Beyond blood glucose**
Monami M. et al. Diabetes Research & Clinical Practice July 2007. epub

66. **Non-invasive AGE-measurements by skin autofluorescence in patients with Type 2 Diabetes Mellitus. Tool for risk-assessment of diabetes complications?**
Lutgers H, et al. Diabetes Care. 2006 Dec;29(12):2654-9

67. **Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy**
Meerwaldt R, et al. Diabetologia. 2005;48:1637-44.

68. **The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation.**
Smit AJ, Lutgers HL.Curr Med Chem. 2004 Oct;11(20):2767-84.

AGE Reader in cardiovascular disease

69. **Diverging effects of diabetes mellitus in patients with peripheral artery disease and abdominal aortic aneurysm and the role of advanced glycation end-products: ARTERY study - protocol for a multicentre cross-sectional study.**
de Vos L.C. et al. BMJ Open. 2017 Apr 11;7(4):e012584. doi: 10.1136/bmjopen-2016-012584.

70. **A Comparative Study on Skin and Plasma Advanced Glycation End Products and Their Associations with Arterial Stiffness.**
Liu C.Y. et al. Pulse (Basel). 2017 Jan;4(4):208-218.

71. **Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease.**
Schutte E et al. Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1709-14.

72. **The Relationship Between Level of End-Products of Tissue Glycation and Pulse Wave Velocity in Non-diabetic Patients With Cardiovascular Disease.**
Ageev F.T. et al. Kardiologiia. 2015;55(6):63-7.

73. **Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease.**
de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1532-7.

74. **Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.**
Yamagishi S.I. et al. Int J Cardiol. 2015 Mar (Epub)

75. **Skin autofluorescence, 5-year mortality, and cardiovascular events in peripheral arterial disease: all that glitters is surely not gold.**
Schmidt AM. Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):697-9.

76. **Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease.**
de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13.

77. **Skin Autofluorescence, a Non-Invasive Marker for AGE Accumulation, Is Associated with the Degree of Atherosclerosis.**
den Dekker MA. et al. PLoS One. 2013 Dec 23;8(12):e83084.

78. **Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years.**
Tiessen AH. et al. Clin Chem Lab Med. 2013 Apr 2:1-7.

79. **Skin Autofluorescence as a Measure of Advanced Glycation End Product Deposition Is Elevated in Peripheral Artery Disease.**
de Vos L.C. et al. Arterioscler Thromb Vasc Biol. 2012 Nov 8. (Epub)

80. **Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations.**
Watfa G. et al. Diabetes Metab. 2012 Jun 13.

81. **Advanced glycation end product associated skin autofluorescence: A mirror of vascular function?**
Hofmann B. et al. Exp Gerontol. 2012 May 12.

82. **Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.**
Hartog J.W. et al. BENEFICIAL investigators. Eur J Heart Fail. 2011 Aug;13(8):899-908.

83. **Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease.**
Noordzij MJ. Int J Cardiovasc Imaging. 2011 Feb. Epub

84. **Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease.**
Lutgers H. et al. Eur J Clin Invest. 2010 ;40(9):812-7

85. **Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.**
Hartog J. et al; Eur. Journal of Heart Failure, 2010 Apr;12(4):397-403

86. **Advanced glycation end products in patients with cerebral infarction.**
Ohnuki Y. Intern Med. 2009;48(8):587-91.

87. **Advanced Glycation End Products and their receptor RAGE in systemic autoimmune diseases - an inflamation propagating factor contributing to accelerated atherosclerosis.**
Nienhuis et al. Autoimmunity, 2009; 42(4): 302-304

88. **Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events**
Mulder D. et al, Netherlands Heart Journal, Volume 17, Number 4, April 2009

89. **Relation between food and drinking habits,and skin autofluorescence and intima media thickness in subjects at high cardiovascular risk**
Jochemsen M. et al: Journal of Food and Nutrition Research Vol. 48, 2009, No. 1, pp. 51–58

90. **Advanced Glycation Endproducts (AGE) in chronic heart failure**
Smit A. et al. Annals of New York Academy of Science 2008; 1126:225-30

91. **Clinical relevance of Advanced Glycation Endproducts for vascular surgery**
Meerwaldt R. et al. Eur J Vasc Endovasc Surg. 2008; 38,125-131

92. **Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products.**
Mulder DJ. et al. Atherosclerosis. 2007:197:217-223

93. **Clinical and prognostic value of Advanced Glycation End-products (AGEs) in chronic heart failure.**
Hartog J. et al Eur J Heart Failure 2007;9:1146-55

94. **Skin Autofluorescence is an independent marker for Acute Myocardial Infarction**
Mulder DJ, et al. Circulation: 2005; 112:II-371.

AGE Reader in renal disease

95. **Skin autofluorescence in acute kidney injury.**
Lavielle A. et al. Crit Care. 2017 Feb 9;21(1):24.

96. **Skin- and Plasmaautofluorescence in hemodialysis with glucose-free or glucose-containing dialysate.**
Ramsauer B, et al. BMC Nephrol. 2017 Jan 5;18(1):5.

97. **Comparing changes in plasma and skin autofluorescence in low-flux versus high-flux hemodialysis.**
Ramsauer B. et al. Int J Artif Organs. 2015 (Epub)

98. **Skin Autofluorescence Is Associated with Endothelial Dysfunction in Uremic Subjects on Hemodialysis.**
Wang CC. et al. PLoS One. 2016 Jan 25;11(1):e0147771.

99. **Skin autofluorescence advanced glycosylation end products (AGEs) as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients.**
Nongnuch A. et al. Nephrology (Carlton). 2015 May 25.

100. **The effect of vegetarian diet on skin autofluorescence measurements in haemodialysis patients.**
Nongnuch A. et al. Br J Nutr. 2015 Mar 12:1-4. (Epub)

101. **Skin Autofluorescence Is a Predictor of Cardiovascular Disease in Chronic Kidney Disease Patients.**
Furuya F. et al. Ther Apher Dial. 2014 Dec 29.

102. **Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis.**
Siriopol D. et al. Int Urol Nephrol. 2014 Nov 26.

103. **Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease.**
Makulska I. et al. Pediatr Nephrol. 2014 Nov 20.

104. **Skin autofluorescence associates with vascular calcification in chronic kidney disease.**
Maku A.Y. et al. Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1784-90

105. **Skin Autofluorescence and All-Cause Mortality in Stage 3 CKD.**
Fraser S.D. et al. Clin J Am Soc Nephrol. 2014 May 29. Epub

106. **Skin Autofluorescence Predicts Cardiovascular Mortality in Patients on Chronic Hemodialysis.**
Kimura H. et al. Ther Apher Dial. 2014 Jan 24

107. **Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study.**
Tanaka K. et al. PLoS One. 2013 Dec 12;8(12):e83799.

108. **Skin and Plasma Autofluorescence During Hemodialysis: A Pilot Study.**
Graaff R. et al. Artif Organs. 2013 Oct 29.

109. **Tissue Advanced Glycation End Product Deposition after Kidney Transplantation.**
Crowley LE et al. Nephron Clin Pract. 2013 Oct 15;124(1-2):54-59.

110. **Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review.**
Arsov S. et al. Clin Chem Lab Med. 2013 Apr 4:1-10.

111. **Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.**
Jiang J. et al. Atherosclerosis. 2012 Sep;224(1):187-94.

112. **Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.**
Siriopol I. et al. Pediatr Nephrol. 2012 Sep 15. (Epub)

113. **Factors influencing skin autofluorescence of patients with peritoneal dialysis.**
Mácsai E. et al. Acta Physiol Hung. 2012 Jun;99(2):216-22.

114. **Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in hemodialysis patients.**
Adachi T. et al. Nephrology (Carlton). 2012 Jul 13. doi: 10.1111/j.1440-1797.2012.01642.x.

115. **Skin Autofluorescence: A Pronounced Marker of Mortality in Hemodialysis Patients.**
Gerrits E. et al. Nephron Extra. 2012 Jan;2(1):184-191.

116. **Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic renal insufficiency.**
Sebeková K. J Ren Nutr. 2012 Jan;22(1):143-8.

117. **Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.**
Oleniuc M. et al. Int Urol Nephrol. 2011 Oct;44(5):1441-9.

118. **Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.**
McIntyre N.J. et al. Clin J Am Soc Nephrol. 2011 Oct;6(10):2356-63.

119. **Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients.**
Nagano M. et al. Nephrology (Carlton). 2011 Mar;16(3):299-303

120. **Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease.**
Smit AJ. et al. Curr Opin Nephrol Hypertens, 2010: 19(6):527-33.

121. **Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients.**
Tanaka K. et al. Nephrol Dial Transplant. doi: 10.1093/ndt/gfq369

122. **Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease.**
Ueno H et al. Metabolism, 2010, doi: 10.1016/j.metabol.2010.04.001

123. **Tissue-Advanced Glycation End Product Concentration in Dialysis Patients**
McIntyre et al; CJASN, 2010; 5(1): 51-55

124. **Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients?**
Arsov S. et al. Nephrol Dial Transplant 2009; 25(3): 885-891

125. **Skin-Autofluorescence Is an Independent Predictor of Graft Loss in Renal Transplant Recipients**
Hartog J. et al, Transplantation • Volume 87, Number 7, April 15, 2009

126. **Advanced Glycation End Products in Renal Failure: An Overview**
Noordzij M. et al, Journal of Renal Care 2008

127. **AGEs, autofluorescence and renal failure**
Gerrits E. et al. Nephrology Dialysis and Transplantation November 25, 2008

128. **Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease**
Ueno H. et al: Metabolism Clinical and Experimental 57 (2008) 1452–1457

129. **Skin Autofluorescence, a measure of tissue advanced glycation endproducts (AGEs), is related to the diastolic function of dialysis patients**
Hartog J. et al. Journal of Cardiac Failure. 2008; 14(7): 596-602

130. **Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients**
Hartog JWL, et al. Nephrol Dial Transpl 2006 Aug;21(8):2263-9

131. **Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation endproducts, predicts mortality in hemodialysis patients**
Meerwaldt R, et al. J Am Soc Nephrol 2005;16:3687-93.

132. **Skin autofluorescence, a noninvasive measure of advanced glycation end product accumulation, is a predictor of mortality in hemodialysis patients**
Meerwaldt R, et al. Ann N Y Acad Sci 2005;1043:911.

133. **Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease.**
Hartog JW. et al. Ann N Y Acad Sci. 2005 Jun;1043:299-307.

134. **Advanced glycation endproducts in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction**
Hartog J. et al. Am J Kidn Dis 2004; 43:966-975

AGE Reader in other diseases

135. **Advanced glycation end-products in morbid obesity and after bariatric surgery: When glycemic memory starts to fail.**
Sánchez E. et al. Endocrinol Diabetes Nutr. 2017 Jan;64(1):4-10.

136. **Advanced glycation end products as a biomarker for incisional hernia.**
Harlaar JJ et al. Hernia. 2017 Apr 12. doi: 10.1007/s10029-017-1610-2. [Epub ahead of print]

137. **Advanced glycation end-products (AGEs) and associations with cardio-metabolic, lifestyle, and dietary factors in a general population: the NQplus study.**
Botros N. et al. Diabetes Metab Res Rev. 2017 Mar 1. doi: 10.1002/dmrr.2892.

138. **Skin advanced glycation end-products evaluation in infants according to the type of feeding and mother's smoking habits.**
Federico G. et al. SAGE Open Med. 2016 Dec 9;4:2050312116682126. doi: 10.1177/2050312116682126.

139. **Skin autofluorescence is associated with arterial stiffness and insulin level in endurance runners and healthy controls - Effects of aging and endurance exercise.**
Couppé C. et al. Exp Gerontol. 2017 May;91:9-14.

140. **The association between skin autofluorescence and mean deviation in patients with open-angle glaucoma.**
Himori N, et al. Br J Ophthalmol. 2016 Dec 9.

141. **Surface Area of Detachment, Proliferative Vitreoretinopathy, and Pulse Pressure, but not AGEs, are Associated With Retinal Redetachment.**
Fokkens BT et al. Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15).

142. **Skin Autofluorescence Examination as a Diagnostic Tool for Mild Cognitive Impairment in Healthy People.**
Igase M. et al. J Alzheimers Dis. 2016 Nov 14. [Epub ahead of print]

143. **Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events.**
Sprenger HG. et al. AIDS. 2016 Oct 18.

144. **The Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot Study.**
Meertens JH et al. PLoS One. 2016 Aug 16;11(8). (FULL TEXT available)

145. **Relationship between advanced glycation end-product accumulation and low skeletal muscle mass in Japanese men and women.**
Kato M. et al. Geriatr Gerontol Int. 2016 Apr 27. Epub.

146. **Advanced glycation endproducts and their receptor in different body compartments in COPD**.
Hoonhorst S.J. et al. Respir Res. 2016 Apr 26; 17:46.

147. **The association between systemic oxidative stress and ocular blood flow in patients with normal-tension glaucoma.**
Himori N. et al. Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):333-41.

148. **Skin Autofluorescence in Systemic Sclerosis Is Related to the Disease and Vascular Damage: A Cross-Sectional Analytic Study of Comparative Groups.**
Dadoniene J. et al. Dis Markers. 2015;2015:837470. Epub

149. **Traditional and emerging indicators of cardiovascular risk in chronic obstructive pulmonary disease.**
John M. et al. Chron Respir Dis. 2016 Mar 10.

150. **A new gender-specific model for skin autofluorescence risk stratification.**
Ahmad M.S. et al. Sci Rep. 2015 May 14;5:10198.

151. **Achilles tendons in people with type 2 diabetes show mildly compromised structure: an ultrasound tissue characterisation study.**
de Jonge S. et al. Br J Sports Med. 2015 Jan 13 (Epub)

152. **Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?**
de Groot L. et al. Rheumatology (Oxford). 2015 Jan 12 (Epub)

153. **Advanced glycation end products in the skin are enhanced in COPD.**
Hoonhorst S.J. et al. Metabolism. 2014 Jun 13. Epub

154. **Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue.**
Couppé C. et. al. Age (Dordr). 2014 Aug;36(4):9665.

155. **Plasma AGEs and skin autofluorescence are increased in COPD.**
Gopal P. et al. Eur Respir J. 2013 May 3. [Epub ahead of print]

156. **Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia.**
Kouidrat Y. et al. J Psychiatr Res. 2013 Apr 21.

157. **Local differences in skin autofluorescence may not reflect similar differences in oxidative stress exposure.**
Hettema M. et al. J Rheumatol. 2013 Feb;40(2):206.

158. **Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma Globotriaosylsphingosine.**
Rombach S.M. et al. Hypertension. 2012 Aug 6. (Epub)

159. **Advanced Glycation Endproducts are increased in RA patients with controlled disease.**
de Groot L. et al. Arthritis Res Ther. 2011 Dec 14;13(6):R205.

160. **Increased skin autofluorescence after colorectal operation reflects surgical stress and postoperative outcome.**
Pol H.W. et al. Am J Surg. 2011 Nov;202(5):583-9.

161. **Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.**
Hettema M.E.. et al. Int J Rheumatol. 2011. Epub

162. **Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men.**
Momma H. Osteoporos Int. 2011 Sep 8. Epub

163. **Skin autofluorescence is high in patients with cirrhosis - further arguing for the implication of Advanced Glycation End products.**
Maury E. et al. J Hepatol. 2011 May;54(5):1079-80.

164. **Skin advanced glycation end product accumulation and muscle strength among adult men.**
Momma H. et al; Eur J Appl Physiol. 2010 (Epub)

165. **Skin Autofluorescence as Marker of Tissue Advanced Glycation End-Products Accumulation in Formerly Preeclamptic Women.**
Coffeng S.M. et al. Hypertens Pregnancy; 2010, Epub

166. **Accumulation of advanced glycation end (AGEs) products in intensive care patients: an observational, prospective study.**
Greven W. et al. BMC Clinical Pathology; 2010: 10 (4)

167. **Increased accumulation of advanced glycation endproducts in patients with Wegener's granulomatosis.**
Leeuw de K et al. Ann Rheum Dis. 2009; 69(3): 625-U191

168. **Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels advanced glycation endproducts**
Nienhuis H. et al: Rheumatology. 2008; 47(10): 1554-1558

169. **Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels of advanced glycation endproducts**
Nienhuis H. et al. Rheumatology; 2008; 47(10): 1554-1558

170. **Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia**
den Hollander NC. et al. J Inherit Metab Dis. 2007. epub ahead of print

171. **Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus.**
de Leeuw K. et al. Rheumatol 2007;45:1551-1556.

172. **Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently preelamptic women**
Blaauw J. et al. Am J Obstet Gynecol. 2006 Sep;195(3):717-22.

173. **Enhanced skin autofluorescence as a marker for oxidative stress in sepsis, a pilot study.**
Mulder DJ, et al. Eur Soc Intensive Care Medicine 2004

AGE Reader (technical) validation

174. **Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations.**
Da Moura Semedo C. et al. Postgrad Med J. 2017 Jan 31. doi: 10.1136/postgradmedj-2016-134579.

175. **Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study.**
van Waateringe R. et al. Eur J Clin Invest. 2016 Mar 22. Epub.

176. **Body mass index, chronological age and hormonal status are better predictors of biological skin age than arm skin autofluorescence in healthy women who have never smoked.**
Randag A.C. et al. Br J Dermatol. 2015 Jul 25.

177. **The skin autofluorescence reflects the posttranslational glycation grade of the matrix protein collagen.**
Jacobs K. et al. Free Radic Biol Med. 2014 Oct;75 Suppl 1:S34

178. **GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence.**
Eny K.M. et al. Diabetologia. 2014 Aug;57(8):1623-34.

179. **Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population.**
Klenovics KS, Diabet Med. 2013 Sep 30. doi: 10.1111/dme.12326. (Epub).

180. **Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue.**
Yue X. et al. Diabet Med. 2011 Jul;28(7):818-23.

181. **Dermal factors influencing measurement of skin autofluorescence.**
Noordzij M.J. et al. Diabetes Technol Ther. 2011 Feb;13(2):165-70

182. **Skin color independent assessment of aging using skin autofluorescence**
Koetsier M. et al. Optics Express, 2010 ;18(14):14416-29

183. **Reference Values of Skin Autofluorescence.**
Koetsier M. et al. Diabetes Technology & Therapeutics 2010; 12(5):399-403

184. **Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is sufficient**
Koetsier M. et al: Optics Express. 2009; 17(2): 509-519

185. **Skin autofluorescence increases postprandially in human subjects**
Stirban A. et al. Diabetes Technology & Therapeutics 2008: 10:200-5

186. **The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress.**
Mulder DJ. et al. Cardiovasc Drugs Ther. 2007 Apr;21(2):91-7.

187. **Skin Autofluorescence, a Novel Marker for Glycation and Oxidative Stress derived Advanced Glycation Endproducts. An Overview of Current Clinical Studies, Evidence and Limitations**
Mulder DJ, et al. Diabetes Technology and Therapeutics 2006; 8.523-535.

188. **Simple noninvasive measurement of skin autofluorescence**
Meerwaldt R, et al. Ann N Y Acad Sci. 2005;1043:290-298.

189. **Instrumentation for the measurement of Autofluorescence in the human skin**
Graaff R et al. Proc. of SPIE Vol. 5692 (SPIE, Bellingham, WA, 2005). pp. 111-118.

190. **Simple non-invasive assessment of advanced glycation endproducts accumulation**
Meerwaldt R et al. Diabetologia 2004; 47:1324-1330

For more information please visit:

www.diagnoptics.com
www.age-reader.com